Epysqli FDA Approval History
FDA Approved: Yes (First approved July 19, 2024)
Brand name: Epysqli
Generic name: eculizumab-aagh
Dosage form: Injection
Company: Samsung Bioepis Co., Ltd.
Epysqli (eculizumab-aagh) is a complement inhibitor biosimilar to Soliris for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Development timeline for Epysqli
| Date | Article |
|---|---|
| Jul 22, 2024 | Approval FDA Approves Epysqli (eculizumab-aagh), a Biosimilar to Soliris |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
